Client received service connection for adenocarcinoma of sigmoid colon status post colectomy resection of large intestine (claimed as GI issues to include colon cancer stage 3 and constipation); evaluation for adenocarcinoma of sigmoid colon status post colectomy resection of large intestine with gastroesophageal reflux disease (GERD) (claimed as GI issues to include colon cancer stage 3 and constipation), which is currently 10 percent disabling, is increased to 100 percent effective January 22, 2019; an evaluation of 60 percent is assigned from February 1, 2020; service connection for metastatic carcinoma to lymph nodes (claimed as metastatic disease cancer) with an evaluation of 100 percent effective January 22, 2019; a non-compensable evaluation is assigned from February 1, 2020; service connection for peripheral neuropathy, right lower extremity with an evaluation of 30 percent effective January 22, 2019; service connection for peripheral neuropathy, left lower extremity with an evaluation of 30 percent effective January 22, 2019; service connection for peripheral neuropathy, right upper extremity with an evaluation of 30 percent effective January 22, 2019; service connection for peripheral neuropathy, left upper extremity with an evaluation of 20 percent effective January 22, 2019. Service connection for residual surgical scars, abdomen with an evaluation of 0 percent effective January 22, 2019. Entitlement to special monthly compensation (S) based on a disability temporarily rated 100 percent with additional service connected disabilities independently ratable as 60 percent or more criteria being met from January 22, 2019 to February 1, 2020; basic eligibility to Dependents’ Educational Assistance based on permanent and total disability status is established from January 22, 2019; service connection for left ankle lateral collateral ligament sprain with degenerative arthritis with an evaluation of 10 percent effective April 23, 2019; and service connection for right ankle lateral collateral ligament sprain with degenerative arthritis with an evaluation of 10 percent effective April 23, 2019.
